Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 14;28(14):1405-1429.
doi: 10.3748/wjg.v28.i14.1405.

Viral hepatitis: Past, present, and future

Affiliations
Review

Viral hepatitis: Past, present, and future

Matthew August Odenwald et al. World J Gastroenterol. .

Abstract

Each hepatitis virus-Hepatitis A, B, C, D, E, and G-poses a distinct scenario to the patient and clinician alike. Since the discovery of each virus, extensive knowledge regarding epidemiology, virologic properties, and the natural clinical and immunologic history of acute and chronic infections has been generated. Basic discoveries about host immunologic responses to acute and chronic viral infections, combined with virologic data, has led to vaccines to prevent Hepatitis A, B, and E and highly efficacious antivirals for Hepatitis B and C. These therapeutic breakthroughs are transforming the fields of hepatology, transplant medicine in general, and public and global health. Most notably, there is even an ambitious global effort to eliminate chronic viral hepatitis within the next decade. While attainable, there are many barriers to this goal that are being actively investigated in basic and clinical labs on the local, national, and international scales. Herein, we discuss pertinent clinical information and recent organizational guidelines for each of the individual hepatitis viruses while also synthesizing this information with the latest research to focus on exciting future directions for each virus.

Keywords: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E; Hepatitis G; Viral Hepatitis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

References

    1. Coulepis AG, Locarnini SA, Westaway EG, Tannock GA, Gust ID. Biophysical and biochemical characterization of hepatitis A virus. Intervirology. 1982;18:107–127. - PubMed
    1. Coulepis AG, Anderson BN, Gust ID. Hepatitis A. Adv Virus Res. 1987;32:129–169. - PubMed
    1. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–6657. - PubMed
    1. Rezende G, Roque-Afonso AM, Samuel D, Gigou M, Nicand E, Ferre V, Dussaix E, Bismuth H, Féray C. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology. 2003;38:613–618. - PubMed
    1. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001;14:38–58. - PMC - PubMed

MeSH terms

Substances